Skip to main content

Advertisement

SpringerLink
Log in

Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

We have previously shown that continuous intra-arterial combination chemotherapy (IACC) might be more effective for advanced hepatocellular carcinoma (aHCC) in patients with HCV-related liver cirrhosis (C-LC) or alcoholic liver cirrhosis (A-LC) than in patients with HBV-related LC (B-LC). However, it is still unknown whether IACC actually improves the prognosis of aHCC patients with liver cirrhosis (LC), because it is difficult to perform a randomized controlled trial for patients with a poor prognosis. The aim of this study was to retrospectively assess the influence of IACC on the prognosis of aHCC.

Methods

Fifty-eight adult Japanese patients who had aHCC and LC underwent repeated trans-arterial chemoembolization (TACE) without IACC between 1990 and 1997 at our hospital (group T), while 43 patients with aHCC and LC received IACC between 2000 and 2008 after undergoing several TACE sessions (group R). The Japan Integrated Staging score (JIS score) of each patient was ≥ 3 at the time of presentation, except for patients with tumor thrombi involving the first or subsequent portal vein branches or those with tumor invasion of the inferior vena cava. The same IACC regimen was repeated for as long as possible in group R.

Results

In group T, 13 patients had B-LC, 37 patients had C-LC, and 8 patients had A-LC, while the respective numbers were 14, 21, and 8 in group R. The median survival time (MST) was 248 days for patients with C-LC in group T and 708 days for those in group R, while it was 253 days for patients with A-LC in group T and 593 days for those in group R. There were significant differences of survival between the two groups. However, MST was 369 days for patients with B-LC in group T and 782 days for those in group R, without a significant difference. In group R, a complete or partial response was achieved after 4 weeks of chemotherapy in 14.3% of patients with B-LC versus 42.9% of patients with C-LC and 37.5% of patients with A-LC.

Conclusions

In LC patients with a JIS score > 3 at diagnosis, multimodal therapy with IACC after TACE prolongs the MST of C-LC or A-LC patients compared with TACE alone, although it does not improve the MST of patients with B-LC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156

    Article  PubMed  CAS  Google Scholar 

  2. Yu MC, Yuan J-M (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127:S72–S78

    Article  PubMed  CAS  Google Scholar 

  3. Bosch FX, Ribes J, Diaz M et al (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5–S16

    Article  PubMed  Google Scholar 

  4. Chuang VP, Wallace S (1981) Hepatic arterial embolization in the treatment of hepatic neoplasms. Radiology 140:51–58

    PubMed  CAS  Google Scholar 

  5. Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397–401

    PubMed  CAS  Google Scholar 

  6. Lin DY, Liaw YF, Lee TY et al (1988) Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology 94:453–456

    PubMed  CAS  Google Scholar 

  7. Ikeda K, Kumada H, Saitoh S et al (1991) Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 68:2150–2154

    Article  PubMed  CAS  Google Scholar 

  8. Llovet JM, Real MI, Montana X et al (2002) Barcelona liver cancer group. Arterial embolization or chemoembolization versus systemic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739

    Article  PubMed  Google Scholar 

  9. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    Article  PubMed  CAS  Google Scholar 

  10. Takayasu K, Arii S, Ikai I et al (2006) Liver cancer study group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 131:461–469

    Article  PubMed  CAS  Google Scholar 

  11. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Onishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928

    Article  PubMed  CAS  Google Scholar 

  12. Nagasue N, Yukaya H, Hamada T, Hirosue S, Kanashima R, Inokuchi K (1984) The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54:1461–1465

    Article  PubMed  CAS  Google Scholar 

  13. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kirishima S, Suga T, Takahashi M (1995) The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 52:295–299

    Article  PubMed  CAS  Google Scholar 

  14. Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, Takahisa Sakai, Deguchi M, Ohmori S, Nakano T (2003) Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 23:1719–1722

    PubMed  CAS  Google Scholar 

  15. Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, Aoyagi S, Takikawa K (1999) Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncology Report 6:587–591

    CAS  Google Scholar 

  16. Nagai H, Sumino Y (2008) Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent Pat Anticancer Drug Discov 3:220–226

    Article  PubMed  CAS  Google Scholar 

  17. Nagai H, Kanayama M, Higami K et al (2007) Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 13(2):280–284

    PubMed  CAS  Google Scholar 

  18. Kanayama M, Nagai H, Sumino Y (2009) Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 64:109–114

    Article  PubMed  CAS  Google Scholar 

  19. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

    Article  PubMed  CAS  Google Scholar 

  20. Moreno-Aspitia A, Morton RF, Hillman DW et al (2009) Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central cancer treatment group and Mayo Clinic Trial N0336. J Clin Oncol 27:11–15

    Article  PubMed  CAS  Google Scholar 

  21. Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300

    Article  PubMed  CAS  Google Scholar 

  22. Iwamiya T, Sawada S, Ohta Y (1994) Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33:S134–S138

    Article  PubMed  Google Scholar 

  23. Wakasa K, Sakurai M, Kuroda C et al (1990) Effect of transcatheter arterial embolization on the boundary architecture of hepatocellular carcinoma. Cancer 65:913–919

    Article  PubMed  CAS  Google Scholar 

  24. Gabrilovich DI, Chen HL, Girgis KR et al (1996) Production of vascular endotherial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103

    Article  PubMed  CAS  Google Scholar 

  25. Ferrara N, Gerber HP, LeCounter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

    Article  PubMed  CAS  Google Scholar 

  26. Korangy F, Ormandy LA, Bleck JS et al (2004) Spontaneous tumor-specific humoral and cellular immune response to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332–4341

    Article  PubMed  CAS  Google Scholar 

  27. Shevach EM (2001) Certified professionals: CD4+ CD25+ suppressor T cell. J Exp Med 193:F41–F46

    Article  PubMed  CAS  Google Scholar 

  28. Stephens LA, Mottet C, Mason D, Powrie F (2001) Human CD4 + CD25 + thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 31:1247–1254

    Article  PubMed  CAS  Google Scholar 

  29. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH (2001) Identification and functional characterization of human CD4 + CD25 + T cells with regulatory properties isolated from peripheral blood. J Exp Med 193:1285–1294

    Article  PubMed  CAS  Google Scholar 

  30. Mosmann TR, Coffman RL (1989) Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145–173

    Article  PubMed  CAS  Google Scholar 

  31. O’Garra A (1998) Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275–283

    Article  PubMed  Google Scholar 

  32. Roitt I (ed) (1997) Essential immunology, 9th edn. Blackwell Science, Malden

    Google Scholar 

  33. Kuby J, Cameron J, Todd C, Mitchell J (2000) Immunology, 4th edn. Freeman and Company, New York

    Google Scholar 

  34. Kobayashi M, Kobayashi H, Polland RB et al (1998) A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160:5869–5873

    PubMed  CAS  Google Scholar 

  35. Zitvogel L, Mayordomo JI, Tjandrawan T et al (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87–97

    Article  PubMed  CAS  Google Scholar 

  36. Tsung K, Meko JB, Peplinski GR et al (1997) IL-12 induces T helper 1-directed antitumor response. J Immunol 158:3359–3365

    PubMed  CAS  Google Scholar 

  37. Weiner GJ, Liu HM, Wooldridge JE et al (1997) Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94:10833–10837

    Article  PubMed  CAS  Google Scholar 

  38. Hu H-M, Urba WJ, Fox BA (1998) Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from Type 2 to a type 1 cytokine profile. J Immunol 161:3033

    PubMed  CAS  Google Scholar 

  39. Nagai H, Miyaki D, Matsui T, Kanayama M, Higami K, Momiyama K, Ikehara T, Watanabe M, Sumino Y, Miki K (2008) Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. Cancer Chemother Pharmacol 62:959–963

    Article  PubMed  CAS  Google Scholar 

  40. Momiyama K, Nagai H, Sumino Y (2009) Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. Cancer Chemother Pharmacol 64:271–277

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 6-11-1, Omorinishi, Ota-ku, Tokyo, 143-8541, Japan

    Hidenari Nagai, Teppei Matsui, Masahiro Kanayama, Noritaka Wakui, Kouichi Momiyama, Manabu Watanabe, Yoshinori Igarashi & Yasukiyo Sumino

Authors
  1. Hidenari Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teppei Matsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahiro Kanayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noritaka Wakui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kouichi Momiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manabu Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshinori Igarashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yasukiyo Sumino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hidenari Nagai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagai, H., Matsui, T., Kanayama, M. et al. Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 68, 139–145 (2011). https://doi.org/10.1007/s00280-010-1465-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1465-z

Keywords

Search

Navigation